Breast cancer 5 year survival rates (UK, 1975) by stage at diagnosis

5-year survival in breast cancer (Europe; 1990)

0 20 40 60 80 100

Switzerland

Finland

France

Italy

Netherlands

Germany

Denmark

England

Spain

Scotland

Estonia

Poland

Five-year survival (%)

J Nat Cancer Inst 1995; 87: 1209J Nat Cancer Inst 1995; 87: 1209

5-year5-yearsurvival (%)survival (%)

No. ofNo. ofpatientspatients

75.775.773.573.571.471.470.870.869.969.968.468.468.168.162.562.562.562.561.861.858.858.843.943.9

2,2432,24311,12311,123

2,4982,4983,5953,5952,6532,6533,3593,359

17,49817,49860,39060,390

1,0431,04311,26111,261

2,3872,3871,0891,089

Breast cancer demographics

Anderson WF et al. Breast Cancer Res Treat 2002; 76: 27–36

24.9

56.9

35.764.3

41.450.18.5

75.1

63.3

20.179.9

28.865.16.1

ER-positive ER-negative

Proportion of patients (%)

Mean age (years)

Age at diagnosis (%)<5050

Tumour size (%)>2.0 cm2.0 cmunknown

Patients (n=82,488)

ER = oestrogen receptor

Prevention data13,388 women

0 1 2 3 4 5

Years on studyDCIS

1804 women

0 1 2 3 4 5

Years on study

Contralateral BC2818 women

0 1 2 3 4 5 6

Years on study

Adjuvant, node negative5217 women

0 1 2 3 4 5 6

Years on study

Adjuvant, node positive2210 women

0 1 2 3 4 5 6

Years on study

Placebo

Tamoxifen

Breast cancer continuum: consistency of results on 5 years of tamoxifen

Breast cancer incidence and mortality

England

France

Germany

Total EU

USA

n

10,846

10,811

17,692

73,592

39,800

n

34,176

35,726

48,098

210,631

211,300

Incidence Mortality

Jemal A et al. CA Cancer J Clin 2003; 53: 5–26; Cancer Research UK. Cancer Stats – Incidence & Mortality UK, April 2003;

Ferlay et al. IARC Press, 1999

Changes in incidence and mortality from breast cancer (UK, 1994)

Incidence

• In the UK in 1992, the incidence of breast cancer was 40% higher than in 1979

• Incidence of breast cancer in the UK (age 50–64) increased steeply following the introduction of screening in 1988

Mortality110

100

90

80

0

110

100

90

80

01950 60 70 80 87 90 94

Year

Screeningintroduced

Age-standardised mortality from breastcancer in women aged 55-69,England and Wales, 1950-94

Quinn M, et al. Br Med J 1995; 311: 1391-1395Quinn M, et al. Br Med J 1995; 311: 1391-1395

Improved Outlook in Early Breast Cancer:Indirect Comparison of ATAC data with EBCTCG 1995 Overview1

(Hormone Receptor +ve Patients >50 Years)

E

stim

ated

per

cen

tag

e st

ill w

ith

ou

t re

curr

ence

as

firs

t ev

ent

100

80

00 1 2 3 4 5+ years

90

70

84.6%

70.5%

3-year event-free rate:

90%92%

*ATAC data truncated at 42 months 1EBCTCG. The Lancet 1998; 351: 1451–1467

Anastrozole (ATAC data)

Tamoxifen (ATAC data)

Tamoxifen (EBCTCG overview)

Control (EBCTCG overview)

Cancer Research UK, 2003

Numberof newcases

Age at diagnosis

450

400

350

300

250

200

150

100

50

0

6000

5000

4000

3000

2000

1000

0 85+80-84

75-79

70-74

65-69

60-64

55-59

50-54

45-49

40-44

35-39

30-34

25-29

20-24

15-19

10-14

0-4

5-9

Rate per100,000population

number

rates

Number of new breast cancer cases diagnosed and age-specific rates per

100,000 population, UK, 1999

Survival from time of tumour recurrence:in all patients with advanced breast cancer

Months

60483624120

Cu

mu

lativ

e S

urv

iva

l1.0

.8

.6

.4

.2

0.0

1974-19791980-19841985-19891990-19941995-2000

Survival in advanced breast cancer

Year of 1st recurrence

Median Survival (months)

3 year OS

(%)

5 year OS

(%)

1974 - 1979 15 15 10

1980 - 1984 17 27 14

1985 - 1989 22 37 22

1990 - 1994 27 43 29

1995 - 2000 58 63 44